MedTrace Logo

A Comparison of Proprietary Formulations of Oral Ketamine + Aspirin and Oral Ketamine Alone for Musculoskeletal Pain

NCT04860804 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-07-17

Study results available
· View outcomes & findings →

Summary

Acute Pain is one of the most frequent chief complaints and the main reason for visiting the Emergency Department (ED). The acute pain in the ED is largely prevalent across the country with recent literature demonstrating that 61-91% of patients are admitted to the ED due to a variety of acute painful syndromes. There is a lack of good options for pain control in such settings.

Conditions

Interventions

DRUG

Aspirin and Ketamine

Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin

DRUG

Oral Ketamine

Proprietary oral formulation of 0.5mg/kg of ketamine

Sponsors & Collaborators

  • Antonios Likourezos

    lead OTHER

Principal Investigators

  • Leily Naraghi Bagher Pour, MD · Maimonides Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-22
Primary Completion
2021-11-30
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04860804 on ClinicalTrials.gov